A new study suggests that rapamycin, an anti-aging drug, may help protect the brains of people genetically predisposed to Alzheimer's disease. Researchers found that four weeks of low-dose treatment improved brain blood flow in healthy middle-aged adults carrying the high-risk APOE4 gene variant, according to the findings. Women in the study showed the strongest benefits from the intervention. The research adds to growing interest in repurposing existing medications for neurodegenerative disease prevention.
The significance lies in timing. Declining brain blood flow can begin years before Alzheimer's symptoms such as memory loss appear, making early intervention a key target for researchers seeking to prevent or delay the disease. By demonstrating measurable vascular improvements in a high-risk group before symptoms emerge, the study raises hopes for pre-symptomatic treatment strategies. However, the trial was small and short-term, and experts caution that larger studies are needed to confirm whether the blood flow gains translate into lasting protection against cognitive decline.
Independent reporting synthesized from primary wires and global correspondents.